Thera-SAbDab

CAMRELIZUMAB

>   Structural Summary
TherapeuticCamrelizumab
TargetPDCD1
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedChinese PLA General Hospital, Hangzhou Cancer Hospital, Incyte Corporation, Jiangsu Hengrui Medicine Co., Nanjing Medical University, Peking University People's Hospital, Sun Yat-Sen University
Conditions ApprovedHodgkin's disease
Conditions ActiveNasopharyngeal cancer, Non-small cell lung cancer, Oesophageal cancer, Liver cancer, Biliary cancer, Cervical cancer, Cholangiocarcinoma, Colorectal cancer, Endometrial cancer, Fallopian tube cancer, Gastric cancer, Osteosarcoma, Ovarian cancer, Pancreatic cancer, Peritoneal cancer, Renal cell carcinoma, Solid tumours, Urogenital cancer, Diffuse large B cell lymphoma, Breast cancer, Malignant melanoma
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]